Galderma to launch first ready-to-use toxin in Europe
Alluzience, a new BoNT-A neuromodulator from Galderma, has become the first ready-to-use toxin approved for use in Europe.
National approval processes will now take place for the product after it received a positive decision from its European approval procedure.
Unlike all other BoNT-A products currently approved in Europe that come in powder form and require reconstitution with sodium chloride before use, Alluzience is a ready-to-use formulation. Galderma says this avoids any calculations and allows for more precision, meaning that the product has the potential to improve safety and dosing accuracy compared with powder- form BoNT-A preperations.
Alluzience is intended for the treatment of frown lines. The European authorisation is based on the data from two trials including one study in which more than 50% of patients demonstrated effects within two to three days.1 An effect was demonstrated for up to six months.1 One month after injection, 85.2% of patients were either “satisfied” or “very satisfied” compared to 9% for placebo patients.1
“At Galderma we pride ourselves on developing innovative products that meet today’s needs, which is underpinned by our longstanding knowledge and heritage in dermatology,” said Alexandre Brennan, head of Galderma’s global business unit for aesthetics. “We know how advantageous it is for doctors to have access to a ready-to-use liquid formulation in Alluzience. It’s for this reason that [this] is an important milestone for both patients and healthcare professionals.”
REFERENCES
1. Ascher B, Rzany B, Kestemont P, et al. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo Controlled Study of a Single Treatment, Ready-to Use Toxin for Moderate-to- Severe Glabellar Lines. Aesthet Surg J. 2020;40(1):93–104.